Babesiosis study in France
Part of Infections clinical trials.
This study looks at cases of babesiosis, a rare tick-borne disease, in France from 2000 to 2024. It aims to understand how the disease affects people.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with babesiosis (confirmed by a blood test or a PCR test)
- You were treated for babesiosis between January 1, 2000, and December 31, 2024
- You agree to take part in the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at people in Alsace, France, who have been diagnosed with anaplasmosis (a tick-borne infection). It aims to understand the disease's patterns and symptoms.
This trial asks general practitioners in France to complete a survey about their knowledge of tick-borne encephalitis (a virus spread by ticks that can cause brain swelling). It helps researchers understand how well doctors know about this disease and how to prevent it.
This study looks at people who got a serious form of Lyme disease while being treated with a type of biologic drug called an anti-CD20 (such as rituximab). The goal is to learn more about these cases and improve care. You may join if you had Lyme disease confirmed by a DNA test within two years of taking this medicine.
This study looks at how foresters in Alsace are exposed to ticks and tick-borne diseases, and how to prevent them. The goal is to better protect forestry workers from these risks.
This study looks back at cases of a rare bacterial infection called Streptobacillus moniliformis in France between 2007 and 2023. It aims to better understand how the infection affects people of all ages.
This study gathers information about blood infections to better understand them and improve care. It may help by providing detailed data on your specific infection.
Hear when a new Human Babesiosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.